Idarucizumab ‘Praxbind’

Chemical

Monoclonal Ab Fragment

Use

Reversal of Dabigatran

• Emergency surgery
• Life threatening bleeding

Presentation

Clear/yellow solution, 50mg/mL

Dose

5mg IV infusion

Route

IV 

Onset

Immediate → terminal half life 10hrs

MoA (mechanism)

• Ab fragment binds Dabigatran
• 300 x affinity for Dabigatran than Dabigatran for Thrombin
• Neutralises anticoagulant activity → of free + thrombin-bound dabigatran

PK

A

D

Remains in intravascular space

M

Protein metabolism of AB’s

E

Clearance 47mL/min

Rapid

Terminal t ½ 10hrs

Adverse Effects

Hypersensitivity